Stemline prices IPO to raise funds for AML study as cash runs low
This article was originally published in Scrip
With just a few million dollars in the bank, US cancer drug developer Stemline Therapeutics set a range of $11 to $13 per share on 19 July for its initial public offering of 3.5 million shares, but did not announce a date for the IPO, which would generate gross proceeds of $45.5 million at the high end of the stock price target.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.